RxDoctor Payments Data

Hall McGee, MD

Ophthalmology · Pittsburgh, PANPI 1215145321

Payments from drug & device makers

$1,353in general payments, 2019–2025

Across 59 payments — averaging $22.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$429
  • Biotissue Holdings Inc.$159
  • Regeneron Healthcare Solutions, Inc.$137
  • Bausch & Lomb Americas Inc.$121
  • Oyster Point Pharma, Inc.$74
  • Tearlab Corp$67
  • plus $366 from 10 others

What the payments were for

  • Food & beverage$1,33699%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,353 in reported general payments places this provider in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$250,355
Medicare patients
604
Services billed
2,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner29$52,482
RestasisCyclosporine37$44,904
MieboPerfluorohexyloctane/Pf52$38,889
Fluorometholone321$38,434
Prednisolone Acetate801$38,397
Cyclosporine46$34,426
XiidraLifitegrast19$23,754
Ketorolac Tromethamine383$16,537
Loteprednol Etabonate60$9,002
MoxifloxacinMoxifloxacin Hcl394$6,605
LumiganBimatoprost16$5,262
Brimonidine Tartrate44$5,014
ValacyclovirValacyclovir Hcl122$4,478
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol11$3,817
Gatifloxacin78$3,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Xiidra$121$62,64371 claims
Tarsus Pharmaceuticals, Inc.Xdemvy$40$52,48229 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$41$9,00260 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →